Table 2.
Study characteristics and quality
| Studies (Author) | Year | Chemotherapy regimena | Number (T/C) | Type of Assessable Outcomes | Jadad Scoresb | |
|---|---|---|---|---|---|---|
| treatment | control | |||||
| Hao XL[20] | 2008 | NP+SFI | NP | 60/68 | WBC/HB/PLT/nausea and vomiting toxicity, KPS | 3 |
| Wang K[21] | 2007 | NP+SFI | NP | 18/18 | tumor response, WBC/PLT toxicity, KPS | 3 |
| Kang GY[22] | 2006 | NP+SFI | NP | 36/36 | tumor response, WBC/PLT/HB/nausea and vomiting toxicity, KPS | 2 |
| Gong ZM[23] | 2008 | NP+SFI | NP | 33/32 | tumor response, WBC/PLT/HB/nausea and vomiting toxicity, KPS | 2 |
| Wang XY[24] | 2007 | NP+SFI | NP | 35/34 | tumor response, WBC/PLT/HB/nausea and vomiting toxicity, | 4 |
| Wang YZ[25] | 2007 | NP+SFI | NP | 28/27 | tumor response, KPS, WBC/PLT/HB toxicity | 3 |
| Li TW[26] | 2009 | NP+SFI | NP | 36/33 | tumor response, the KPS | 4 |
| Li Y[27] | 2007 | NP+SFI | NP | 44/43 | tumor response, WBC/PLT/nausea and vomiting toxicity, | 4 |
| Lv J[28] | 2008 | NP+SFI | NP | 40/40 | tumor response, WBC/PLT/HB/nausea and vomiting toxicity, KPS | 4 |
| Zhao ZY[29] | 2007 | NP+SFI | NP | 35/34 | tumor response, WBC/PLT/HB nausea and vomiting toxicity, | 4 |
| Geng L[30] | 2004 | NP+SFI | NP | 25/15 | tumor response, KPS | 2 |
| Yu QZ[31] | 2007 | NP+SFI | NP | 30/32 | tumor response, KPS | 4 |
| Liu CL[32] | 2004 | NP+SFI | NP | 60/60 | tumor response, WBC/PLT/HB toxicity | 2 |
| Liu PH[33] | 2007 | NP+SFI | NP | 30/30 | tumor response, KPS | 1 |
| Pan YK[34] | 2008 | NP+SFI | NP | 45/45 | tumor response, WBC/PLT/HB toxicity | 2 |
| Zheng JH[35] | 2009 | NP+SFI | NP | 42/42 | tumor response, WBC/PLT/HB/nausea and vomiting toxicity | 4 |
| Miao SR[36] | 2010 | NP+SFI | NP | 38/41 | tumor response, the KPS, WBC/PLT/nausea and vomiting toxicity | 3 |
| Li YQ[37] | 2010 | NP+SFI | NP | 43/42 | KPS | 5 |
| Geng D[38] | 2007 | NP+SFI | NP | 42/26 | tumor response, WBC/the nausea and vomiting toxicity | 2 |
| Zou Y[39] | 2005 | TP+SFI | TP | 24/24 | tumor response, KPS | 3 |
| Luo SZ[40] | 2006 | TP+SFI | TP | 25/25 | tumor response, KPS, WBC/PLT/nausea and vomiting toxicity | 2 |
| Luo SW[41] | 2007 | TP+SFI | TP | 30/30 | tumor response, WBC/PLT/HB/nausea and vomiting toxicity, KPS | 2 |
| Zhang FL[42] | 2008 | TP+SFI | TP | 30/30 | tumor response, WBC/PLT/HB/nausea and vomiting toxicity, KPS | 3 |
| Zhao YX[43] | 2009 | TP+SFI | TP | 40/40 | tumor response, KPS | 2 |
| Yu F[44] | 2007 | DC+SFI | DC | 30/30 | tumor response, WBC/PLT/HB toxicity | 4 |
| He WJ[45] | 2008 | GP+SFI | GP | 35/35 | tumor response, WBC/PLT/HB/nausea and vomiting toxicity, KPS | 3 |
| Liang K[46] | 2010 | GP+SFI | GP | 39/37 | tumor response, KPS, | 2 |
| Chen J[47] | 2007 | TP/NP+SFI | TP/NP | 41/39 | tumor response, KPS | 2 |
| Wu L[48] | 2004 | TP/NP+SFI | TP/NP | 30/30 | tumor response, WBC toxicity | 5 |
Abbreviations: SFI, shenqi fuzheng injection; NP, vinorelbine, cisplatin; TP, paclitaxel, carboplatin; DC, docetaxel cisplatin; GP, gemcitabine cisplatin;T/C, treatment group/control group; KPS, Karnofsky Performance status; WBC, white blood cell; PLT, platelet; HB, hemoglobin;
a: all patients included in studies in both groups received systemic chemotherapy therapy, and no patients received surgery and radiation, The only difference between the two groups was whether they received SFI.
b: modified Jadad scale was used.